Clinical Trial Equipment & Ancillary Solutions Market Report 2022-2030: Featuring Key Players Ancillare, Imperial, Thermo Fisher Scientific & Others

The “Clinical Trial Equipment & Ancillary Solutions Market Size, Share & Trends Analysis Report by Product (Sourcing, Supply/Logistics), by Phase (Phase I, II, III, IV), by Region (APAC, North America), and Segment Forecasts, 2022-2030″ report has been added to ResearchAndMarkets.com’s offering.

The global clinical trial equipment & ancillary solutions market is expected to reach USD 5.09 billion by 2030, expanding at a CAGR of 8.1% over the forecast period. The growing pharmaceutical and medical sectors, globalization of clinical trials, and rising R&D expenditure are the factors driving the market.

The clinical trial procedure has evolved considerably in recent years. Complex clinical studies are creating new problems throughout the healthcare supply chain. Modern studies frequently involve huge numbers of patients and patient subgroups, as well as numerous nations and research sites.

As a result, the number of challenges that supply chain managers confront while working with clinical trial equipment & ancillaries has increased. Renting medical equipment relieves the burden of storage, retrieval, and disposal. Another important decision-making reason is that renting equipment reduces significant upfront expenses and large investments required to furnish licensed clinical trial locations.

Clinical Trial Equipment & Ancillary Solutions Market Report Highlights

  • The supply/logistics product segment dominated the market with a revenue share of more than 38% in 2021 due to the high number of clinical trials globally, which resulted in increased demand for efficient logistics services.
  • The phase III segment accounted for the maximum revenue share of 53.9% in the global market in 2021. Phase III studies are the most effective approach to discovering a new treatment standard.
  • North America led the global market in 2021 and is expected to remain dominant even during the forecast years due to a rise in the number of CRO and pharmaceutical & medical companies in the region.
  • Asia Pacific is projected to be the registered fastest-growing CAGR of 9.5% during the forecast period as it is becoming an increasingly significant site for clinical trial investigations.

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Clinical Trial Equipment & Ancillary Solutions Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Evolving Clinical Trials Needs
3.3.1.2 Rising Investment In R&D
3.3.1.3 Growing Pharmaceutical & Medical Devices Industry
3.3.2 Market Restraint Analysis
3.3.2.1 Rising Cost Of Clinical Trials

Chapter 4 Clinical Trial Equipment & Ancillary Solutions Market: Product Segment Analysis

Chapter 5 Clinical Trial Equipment & Ancillary Solutions Market: Phaseanalysis

Chapter 6 Clinical Trial Equipment & Ancillary Solutions Market: Regional Analysis

Companies Mentioned

  • Ancillare Lp
  • Imperial Crs
  • Woodley Equipment Company Ltd
  • Thermo Fisher Scientific Inc.
  • Ppd, Inc
  • Parexel International Corporation
  • Medicapital Rent (Emsere)
  • Quipment Sas
  • Irm
  • Marken a Ups Company
  • Myonex
  • Yourway

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”